SMARCA4 biology in alveolar rhabdomyosarcoma.
Bharathy N, Cleary MM, Kim JA, Nagamori K, Crawford KA, Wang E, Saha D, Settelmeyer TP, Purohit R, Skopelitis D, Chang K, Doran JA, Kirschbaum CW, Bharathy S, Crews DW, Randolph ME, Karnezis AN, Hudson-Price L, Dhawan J, Michalek JE, Ciulli A, Vakoc CR, Keller C.
Bharathy N, et al. Among authors: kirschbaum cw.
Oncogene. 2022 Mar;41(11):1647-1656. doi: 10.1038/s41388-022-02205-0. Epub 2022 Jan 29.
Oncogene. 2022.
PMID: 35094009
Free PMC article.
Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell de …
Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not sho …